Insider Buying: Sanofi Acquires 175,000 Shares of Regeneron Pharmaceuticals Stock (REGN)
Regeneron Pharmaceuticals (NASDAQ:REGN) major shareholder Sanofi acquired 175,000 shares of the company’s stock in a transaction that occurred on Thursday, July 10th. The shares were purchased at an average price of $311.08 per share, for a total transaction of $54,439,000.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
REGN has been the subject of a number of recent research reports. Analysts at Morgan Stanley reiterated a “positive” rating on shares of Regeneron Pharmaceuticals in a research note on Thursday. They now have a $310.00 price target on the stock. Separately, analysts at Zacks upgraded shares of Regeneron Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Wednesday, June 25th. They now have a $334.00 price target on the stock. Finally, analysts at Goldman Sachs reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, June 24th. Five equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $343.44.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 0.58% during mid-day trading on Monday, hitting $317.95. 700,038 shares of the company’s stock traded hands. Regeneron Pharmaceuticals has a one year low of $227.64 and a one year high of $352.49. The stock’s 50-day moving average is $303.2 and its 200-day moving average is $302.2. The company has a market cap of $31.384 billion and a P/E ratio of 90.63.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.58 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.94 by $0.36. The company had revenue of $626.00 million for the quarter, compared to the consensus estimate of $609.04 million. During the same quarter in the prior year, the company posted $1.78 earnings per share. The company’s quarterly revenue was up 42.3% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals will post $9.89 EPS for the current fiscal year.
Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.